Mirada Medical Announces The Release Of Its Advanced Oncology Fusion Package Available Within Vitrea Enterprise Suite From Vital Images
Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced recently that its latest XD3 multi-modality image fusion analysis package (Oncology Fusion) is now available as a fully integrated option within Vitrea Enterprise Suite (VES) from Vital Images. The integrated solution is designed to increase productivity and workflow efficiency.
Oncology Fusion enables the visualization, quantification and tracking of tumors with rigid and deformable fusion algorithms for CT, MR, PET and SPECT. Integrated within VES, Vital Images' comprehensive advanced visualization and image distribution solution, users are able to access Oncology Fusion directly from their Vital Images solution, which also enables anywhere access via a Web browser. Oncology Fusion is designed to deliver improved levels of productivity for radiologists and other users of medical imaging who want to access the most advanced applications and workflows on a single unified platform.
Oncology Fusion provides quantifications such as SUV measurements and access to standard disease response protocols such as RECIST for CT and PERCIST for PET and PETCT. The Mirada software supports comparison of two or more PET/CTs and also allows users to fuse MRI with PET, SPECT or CT. Mirada's Oncology Fusion application also incorporates the latest versions of Mirada's leading deformable image registration algorithms, which allow any combination of image modalities to be registered non-rigidly allowing for corrections to be made where patient positioning is inconsistent, or patient anatomy has changed over time.
Commenting on the new product release, Hugh Bettesworth, CEO of Mirada Medical, said: "It is central to Mirada's philosophy that we make the advanced technologies available to the widest range of clinical users. By tightly integrating our Oncology Fusion application with the Vital Enterprise Server, users of this system can experience what we believe are the leading multi-modality workflows available anywhere, and in a way that can significantly boost productivity allowing more scans to be accurately analysed and reported."
"Offering Oncology Fusion within VES supports our commitment to supporting multiple modalities and comprehensive clinical functionality to our customers," commented Erkan Akyuz, executive vice president of product strategy and development at Vital Images.
About Mirada Medical
Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with advanced software applications for the quantification of images which are typically used in cancer diagnosis and treatment response assessment. Mirada Medical's technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada's advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient's condition. Mirada's products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.
Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world's leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada's products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.
The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information, visit www.mirada-medical.com.
About Oncology Fusion
Mirada's XD3 multi-modality clinical reading application empowers radiologists and oncologists with the image analysis they need to diagnose disease and assess follow up to treatment. XD3 combines powerful registration technologies with serial review of acquisitions acquired over time. Key product features include disease specific oncology workflows and fast, accurate and reproducible image quantification, Mirada's world class image registration engine powers multi-modal fusion and registration across time. XD3 facilitates advanced clinical decision support and may be deployed on PACS, workstation or laptop, providing the most flexible workflow integration available anywhere. Mirada Medical continues to develop superior products to suit the needs of clinicians for reviewing images in diagnosing, staging and evaluating disease progression and response to therapy. Mirada's XD3 product provides comprehensive levels of analytical power to the clinical user. Featuring powerful disease specific oncology workflows and fast, accurate and reproducible image quantification, XD3 facilitates advanced clinical decision support. XD3 may be deployed on PACS, home workstation or laptop, providing the most productive workflow integration available anywhere.
SOURCE: Mirada Medical Limited